Switch to:
Also traded in: Germany, Israel, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.01
OPK's Cash-to-Debt is ranked lower than
62% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. OPK: 1.01 )
Ranked among companies with meaningful Cash-to-Debt only.
OPK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13  Med: 13.08 Max: No Debt
Current: 1.01
Equity-to-Asset 0.76
OPK's Equity-to-Asset is ranked higher than
71% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. OPK: 0.76 )
Ranked among companies with meaningful Equity-to-Asset only.
OPK' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.41  Med: 0.69 Max: 0.96
Current: 0.76
-0.41
0.96
Debt-to-Equity 0.06
OPK's Debt-to-Equity is ranked higher than
84% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. OPK: 0.06 )
Ranked among companies with meaningful Debt-to-Equity only.
OPK' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.44  Med: 0.09 Max: 38.41
Current: 0.06
-3.44
38.41
Debt-to-EBITDA -4.60
OPK's Debt-to-EBITDA is ranked lower than
99.99% of the 503 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.74 vs. OPK: -4.60 )
Ranked among companies with meaningful Debt-to-EBITDA only.
OPK' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.6  Med: -0.74 Max: 3.44
Current: -4.6
-4.6
3.44
Piotroski F-Score: 1
Altman Z-Score: 3.50
Beneish M-Score: -2.43
WACC vs ROIC
15.31%
-3.46%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -12.01
OPK's Operating Margin % is ranked lower than
78% of the 781 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. OPK: -12.01 )
Ranked among companies with meaningful Operating Margin % only.
OPK' s Operating Margin % Range Over the Past 10 Years
Min: -31624.44  Med: -82.69 Max: -6
Current: -12.01
-31624.44
-6
Net Margin % -6.52
OPK's Net Margin % is ranked lower than
76% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.12 vs. OPK: -6.52 )
Ranked among companies with meaningful Net Margin % only.
OPK' s Net Margin % Range Over the Past 10 Years
Min: -31688.9  Med: -92.47 Max: -2.05
Current: -6.52
-31688.9
-2.05
ROE % -3.70
OPK's ROE % is ranked lower than
72% of the 803 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.08 vs. OPK: -3.70 )
Ranked among companies with meaningful ROE % only.
OPK' s ROE % Range Over the Past 10 Years
Min: -3196.93  Med: -20.87 Max: -1.23
Current: -3.7
-3196.93
-1.23
ROA % -2.78
OPK's ROA % is ranked lower than
71% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. OPK: -2.78 )
Ranked among companies with meaningful ROA % only.
OPK' s ROA % Range Over the Past 10 Years
Min: -1352.71  Med: -13.26 Max: -0.83
Current: -2.78
-1352.71
-0.83
ROC (Joel Greenblatt) % -62.64
OPK's ROC (Joel Greenblatt) % is ranked lower than
80% of the 817 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.08 vs. OPK: -62.64 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OPK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -130662.93  Med: -258.52 Max: -38.15
Current: -62.64
-130662.93
-38.15
3-Year Revenue Growth Rate 101.30
OPK's 3-Year Revenue Growth Rate is ranked higher than
98% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. OPK: 101.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OPK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 26 Max: 152
Current: 101.3
0
152
3-Year EPS without NRI Growth Rate -46.30
OPK's 3-Year EPS without NRI Growth Rate is ranked lower than
95% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. OPK: -46.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OPK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -69.4  Med: -9.3 Max: 152.4
Current: -46.3
-69.4
152.4
GuruFocus has detected 3 Warning Signs with OPKO Health Inc OPK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OPK's 30-Y Financials

Financials (Next Earnings Date: 2017-11-07)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

OPK Guru Trades in Q3 2016

George Soros 59,837 sh (New)
Jim Simons 1,412,757 sh (New)
John Burbank 12,234 sh (New)
Joel Greenblatt 535,214 sh (+100.09%)
Paul Tudor Jones 36,248 sh (+33.40%)
Ken Fisher 38,229 sh (+1.07%)
Mario Gabelli 97,050 sh (unchged)
Murray Stahl 60,179 sh (-9.28%)
» More
Q4 2016

OPK Guru Trades in Q4 2016

Ken Fisher 39,229 sh (+2.62%)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
John Burbank Sold Out
George Soros Sold Out
Mario Gabelli 94,550 sh (-2.58%)
Murray Stahl 58,149 sh (-3.37%)
Joel Greenblatt 167,109 sh (-68.78%)
» More
Q1 2017

OPK Guru Trades in Q1 2017

Paul Tudor Jones 93,342 sh (New)
Murray Stahl 58,941 sh (+1.36%)
Mario Gabelli 94,550 sh (unchged)
Joel Greenblatt Sold Out
Ken Fisher 38,979 sh (-0.64%)
» More
Q2 2017

OPK Guru Trades in Q2 2017

Jim Simons 1,615,691 sh (New)
Murray Stahl 61,934 sh (+5.08%)
Mario Gabelli 94,550 sh (unchged)
Paul Tudor Jones Sold Out
Ken Fisher 38,229 sh (-1.92%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:OPK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-06-30 Reduce -1.92%$6.14 - $8 $ 6.62-6%38,229
Ken Fisher 2017-03-31 Reduce -0.64%$7.43 - $9.38 $ 6.62-21%38,979
Joel Greenblatt 2017-03-31 Sold Out 0.02%$7.43 - $9.38 $ 6.62-21%0
Joel Greenblatt 2016-12-31 Reduce -68.78%0.05%$9.13 - $11.91 $ 6.62-36%167,109
Mario Gabelli 2016-12-31 Reduce -2.58%$9.13 - $11.91 $ 6.62-36%94,550
Ken Fisher 2016-12-31 Add 2.62%$9.13 - $11.91 $ 6.62-36%39,229
George Soros 2016-12-31 Sold Out 0.02%$9.13 - $11.91 $ 6.62-36%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:SZSE:000513, SZSE:000623, NSE:DIVISLAB, SZSE:300142, LSE:HIK, TSE:4530, NAS:AKRX, SZSE:000999, SZSE:002001, SHSE:600521, SHSE:600079, HKSE:00460, NSE:ALKEM, NYSE:MNK, SHSE:600511, HKSE:00867, SZSE:002219, SZSE:300558, XTER:EVT, SHSE:600566 » details
Traded in other countries:XCY.Germany, OPK.Israel, OPK.Mexico,
Headquarter Location:USA
OPKO Health Inc is a diversified healthcare company. Its business includes diagnostics and provision of pharmaceutical products.

Opko Health is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a global supply-chain operation and holding company in Ireland. Opko also owns a specialty active pharmaceutical ingredients manufacturer in Israel. The company's bio-reference testing business consists of routine testing and esoteric testing. Routine tests measure various health parameters, such as the functions of the heart, kidney, liver, thyroid, and other organs.

Top Ranked Articles about OPKO Health Inc

OPKO Health Enters into Exclusive Agreement with Japan Tobacco to Develop and Commercialize RAYALDEE® in Japan
Weekly CEO Buys Highlights Insiders invest in OPKO Health, Cleveland-Cliffs, Lexicon Pharmaceuticals, Delek Logistics Partners and Radius Health
According to GuruFocus Insider Data, these are the largest CEO buys during the past week.  Read more...
Weekly Top Insider Buys Highlight for the Week of Sept. 22 The largest Insider Buys were for Sysco Corp. (SYY), OPKO Health Inc. (OPK), Cypress Semiconductor Corp. (CY), and United Continental Holdings Inc. (UAL).
The largest Insider Buys this week were for Sysco Corp. (NYSE:SYY), OPKO Health Inc. (NASDAQ:OPK), Cypress Semiconductor Corp. (NASDAQ:CY), and United Continental Holdings Inc. (NYSE:UAL). Read more...
OPKO’s BioReference Laboratories and The Garage Announce National Strategic Affiliation to Enhance Value-Based Care
Weekly CEO Buys Highlights Insiders purchase American Assets, OPKO Health, Inovalon Holdings, RH and NGL Energy Partners
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. Read more...
Stocks That Fell to Three-Year Lows in the Week of Sept. 15 Mednax Inc., OPKO Health Inc., Terra Nitrogen Co. and Dean Foods Co. have declined to their respective three-year lows
Mednax Inc. (NYSE:MD), OPKO Health Inc. (NASDAQ:OPK), Terra Nitrogen Co. LP (NYSE:TNH) and Dean Foods Co. (NYSE:DF) have declined to their three-year lows. Read more...
OPKO’s GeneDx to Showcase Leadership in Genetic Testing at the National Society of Genetic Counselors and the American Society of Human Genetics Annual Meetings
OPKO Health to Present at Upcoming September Conferences
Weekly CEO Buys Highlights Insiders buy Teradata, OPKO, Mattel and 8x8
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. Read more...
OPKO Health to Announce 2017 Second Quarter Financial Results on August 8, 2017

Ratios

vs
industry
vs
history
PB Ratio 1.74
OPK's PB Ratio is ranked higher than
69% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. OPK: 1.74 )
Ranked among companies with meaningful PB Ratio only.
OPK' s PB Ratio Range Over the Past 10 Years
Min: 1.59  Med: 8.22 Max: 800
Current: 1.74
1.59
800
PS Ratio 3.13
OPK's PS Ratio is ranked lower than
54% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. OPK: 3.13 )
Ranked among companies with meaningful PS Ratio only.
OPK' s PS Ratio Range Over the Past 10 Years
Min: 2.81  Med: 31.15 Max: 158.13
Current: 3.13
2.81
158.13
EV-to-EBIT -28.65
OPK's EV-to-EBIT is ranked lower than
99.99% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.28 vs. OPK: -28.65 )
Ranked among companies with meaningful EV-to-EBIT only.
OPK' s EV-to-EBIT Range Over the Past 10 Years
Min: -130.8  Med: -34.15 Max: 203.7
Current: -28.65
-130.8
203.7
EV-to-EBITDA -132.05
OPK's EV-to-EBITDA is ranked lower than
99.99% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.61 vs. OPK: -132.05 )
Ranked among companies with meaningful EV-to-EBITDA only.
OPK' s EV-to-EBITDA Range Over the Past 10 Years
Min: -146.6  Med: -34.9 Max: 539.9
Current: -132.05
-146.6
539.9
EV-to-Revenue 3.13
OPK's EV-to-Revenue is ranked lower than
52% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.07 vs. OPK: 3.13 )
Ranked among companies with meaningful EV-to-Revenue only.
OPK' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.8  Med: 33.6 Max: 161.4
Current: 3.13
2.8
161.4
Current Ratio 1.67
OPK's Current Ratio is ranked lower than
66% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. OPK: 1.67 )
Ranked among companies with meaningful Current Ratio only.
OPK' s Current Ratio Range Over the Past 10 Years
Min: 0.88  Med: 5.1 Max: 415
Current: 1.67
0.88
415
Quick Ratio 1.50
OPK's Quick Ratio is ranked lower than
60% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.94 vs. OPK: 1.50 )
Ranked among companies with meaningful Quick Ratio only.
OPK' s Quick Ratio Range Over the Past 10 Years
Min: 0.48  Med: 4.68 Max: 415
Current: 1.5
0.48
415
Days Inventory 26.76
OPK's Days Inventory is ranked higher than
93% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.98 vs. OPK: 26.76 )
Ranked among companies with meaningful Days Inventory only.
OPK' s Days Inventory Range Over the Past 10 Years
Min: 25.94  Med: 191.87 Max: 500.07
Current: 26.76
25.94
500.07
Days Sales Outstanding 77.62
OPK's Days Sales Outstanding is ranked lower than
54% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. OPK: 77.62 )
Ranked among companies with meaningful Days Sales Outstanding only.
OPK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.86  Med: 153.78 Max: 727.85
Current: 77.62
38.86
727.85
Days Payable 36.43
OPK's Days Payable is ranked lower than
80% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 68.69 vs. OPK: 36.43 )
Ranked among companies with meaningful Days Payable only.
OPK' s Days Payable Range Over the Past 10 Years
Min: 31.85  Med: 108.04 Max: 1499.3
Current: 36.43
31.85
1499.3

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.60
OPK's 3-Year Average Share Buyback Ratio is ranked lower than
68% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. OPK: -10.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OPK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -146.3  Med: -14.4 Max: 0.4
Current: -10.6
-146.3
0.4

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 220.67
OPK's Price-to-Tangible-Book is ranked lower than
99% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. OPK: 220.67 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
OPK' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.35  Med: 10.28 Max: 850
Current: 220.67
0.35
850
Price-to-Intrinsic-Value-Projected-FCF 2.64
OPK's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
55% of the 306 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.32 vs. OPK: 2.64 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
OPK' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 2.62  Med: 9.57 Max: 177.5
Current: 2.64
2.62
177.5
Price-to-Median-PS-Value 0.10
OPK's Price-to-Median-PS-Value is ranked higher than
99% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.04 vs. OPK: 0.10 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OPK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.1  Med: 1.31 Max: 30
Current: 0.1
0.1
30
Earnings Yield (Greenblatt) % -3.47
OPK's Earnings Yield (Greenblatt) % is ranked lower than
75% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. OPK: -3.47 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OPK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -26.7  Med: -2.8 Max: 0.5
Current: -3.47
-26.7
0.5

More Statistics

Revenue (TTM) (Mil) $1,183.83
EPS (TTM) $ -0.16
Beta2.24
Short Percentage of Float21.73%
52-Week Range $5.85 - 12.15
Shares Outstanding (Mil)559.40

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 1,230 1,370 1,527 1,763
EPS ($) -0.19 -0.04 0.05 0.31
EPS without NRI ($) -0.19 -0.04 0.05 0.31
EPS Growth Rate
(Future 3Y To 5Y Estimate)
12.00%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 11
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}